Form 4: Schrodinger Executive Robert Lorne Abel Reports Stock Option Grant

Robert Lorne Abel, EVP and Chief Scientific Officer at Schrodinger, Inc., reported the grant of stock options on March 4, 2024.

Summary

• Robert Lorne Abel, an executive at Schrodinger, Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Abel on March 4, 2024.
• Abel received options to purchase 60,000 shares of Schrodinger's common stock at an exercise price of $25.24 per share.
• The options vest with respect to 25% of the shares on March 4, 2025, and the remainder vest in equal monthly installments through March 4, 2028.
• Following the transaction, Abel directly owns options for 60,000 shares.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It reflects standard executive compensation practices.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the technology and pharmaceutical industries, used to incentivize performance and retain key personnel.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns executive interests with company performance.

Key Dates